The oxygen demands of the human body require the constant circulation of blood carrying
an enormous concentration of hemoglobin (Hb). Oxygen transport depends not only on the …

In an attempt to find new types of anti‐sickling agents that specifically bind to intracellular
sickle haemoglobin (HbS) without inhibition by plasma and tissue proteins or other …

Recent interest in therapies for sickle cell anemia based on elevating fetal Hb has made
accurate estimates of the sparing effect of fetal Hb (Hb F) and other non-sickle Hbs on sickle …

The sickle cell disorders (SCD) comprise homozygous sickle cell anaemia (SS), SS with~ t-
thalassaemia, sickle cell/haemoglobin C disease (SC), sickle cell/fl-thalassaemia, and other …

The primary pathophysiological event in sickling is the intracellular polymerization of
deoxygenated haemoglobin S. Tucaresol (589C80; 4 [2‐formyl‐3‐hydroxy‐phenoxymethyl] …

Sickle cell disease (SCD) is an inherited disorder of hemoglobin (Hb); approximately
300,000 babies are born worldwide with SCD each year. In SCD, fibers of polymerized …

1. Tucaresol is an orally administered antisickling agent which increases the oxygen affinity
of haemoglobin. 2. The pharmacokinetics, effects on moderate graded exercise and …

Eight subjects with sickle-cell disease in the symptom-free steady-state received a single
one-hour infusion of the new anti-sickling agent BW12C on a total of eleven occasions. A …

Introduction In sickle cell disease (SCD), a single amino acid substitution at β6 of the
hemoglobin (Hb) chain replaces glutamate with valine, forming HbS instead of the normal …

1. Tucaresol (589C80; 4 [2‐formyl‐3‐hydroxyphenoxymethyl] benzoic acid) interacts
stoichiometrically with haemoglobin to increase oxygen affinity. By decreasing the …